Cinzia Federico1, Jennifer Sun1, Barbara Muz2, Kinan Alhallak1, Pippa F Cosper3, Naoshad Muhammad2, Amanda Jeske1, Amanda Hinger2, Stephanie Markovina4, Perry Grigsby4, Julie K Schwarz4, Abdel Kareem Azab5. 1. Department of Radiation Oncology, Cancer Biology Division, Washington University in St Louis School of Medicine, St Louis, Missouri; Department of Biomedical Engineering, Washington University in St Louis McKelvey School of Engineering, St Louis, Missouri. 2. Department of Radiation Oncology, Cancer Biology Division, Washington University in St Louis School of Medicine, St Louis, Missouri. 3. Department of Radiation Oncology, Cancer Biology Division, Washington University in St Louis School of Medicine, St Louis, Missouri; Department of Human Oncology, University of Wisconsin in Madison, Madison, Wisconsin. 4. Department of Radiation Oncology, Cancer Biology Division, Washington University in St Louis School of Medicine, St Louis, Missouri; Alvin J. Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri. 5. Department of Radiation Oncology, Cancer Biology Division, Washington University in St Louis School of Medicine, St Louis, Missouri; Department of Biomedical Engineering, Washington University in St Louis McKelvey School of Engineering, St Louis, Missouri; Alvin J. Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri. Electronic address: kareem.azab@wustl.edu.
Abstract
PURPOSE: Cervical cancer represents the fourth most frequent malignancy in the world among women, and mortality has remained stable for the past 4 decades. Intravenous cisplatin with concurrent radiation therapy is the standard-of-care for patients with local and regional cervical cancer. However, cisplatin induces serious dose-limiting systemic toxicities and recurrence frequently occurs. In this study, we aimed to develop an intracervical drug delivery system that allows cisplatin release directly into the tumor and minimize systemic side effects. METHODS AND MATERIALS: Twenty patient biopsies and 5 cell lines treated with cisplatin were analyzed for platinum content using inductively coupled plasma mass spectrometry. Polymeric implants loaded with cisplatin were developed and evaluated for degradation and drug release. The effect of local or systemic cisplatin delivery on drug biodistribution as well as tumor burden were evaluated in vivo, in combination with radiation therapy. RESULTS: Platinum levels in patient biopsies were 6-fold lower than the levels needed for efficacy and radiosensitization in vitro. Cisplatin local delivery implant remarkably improved drug specificity to the tumor and significantly decreased accumulation in the blood, kidney, and other distant normal organs, compared with traditional systemic delivery. The localized treatment further resulted in complete inhibition of tumor growth. CONCLUSIONS: The current standard-of-care systemic administration of cisplatin provides a subtherapeutic dose. We developed a polymeric drug delivery system that delivered high doses of cisplatin directly into the cervical tumor, while lowering drug accumulation and consequent side effects in normal tissues. Moving forward, these data will be used as the basis of a future first-in-human clinical trial to test the efficacy of localized cisplatin as adjuvant or neoadjuvant chemotherapy in local and regional cervical cancer.
PURPOSE: Cervical cancer represents the fourth most frequent malignancy in the world among women, and mortality has remained stable for the past 4 decades. Intravenous cisplatin with concurrent radiation therapy is the standard-of-care for patients with local and regional cervical cancer. However, cisplatin induces serious dose-limiting systemic toxicities and recurrence frequently occurs. In this study, we aimed to develop an intracervical drug delivery system that allows cisplatin release directly into the tumor and minimize systemic side effects. METHODS AND MATERIALS: Twenty patient biopsies and 5 cell lines treated with cisplatin were analyzed for platinum content using inductively coupled plasma mass spectrometry. Polymeric implants loaded with cisplatin were developed and evaluated for degradation and drug release. The effect of local or systemic cisplatin delivery on drug biodistribution as well as tumor burden were evaluated in vivo, in combination with radiation therapy. RESULTS: Platinum levels in patient biopsies were 6-fold lower than the levels needed for efficacy and radiosensitization in vitro. Cisplatin local delivery implant remarkably improved drug specificity to the tumor and significantly decreased accumulation in the blood, kidney, and other distant normal organs, compared with traditional systemic delivery. The localized treatment further resulted in complete inhibition of tumor growth. CONCLUSIONS: The current standard-of-care systemic administration of cisplatin provides a subtherapeutic dose. We developed a polymeric drug delivery system that delivered high doses of cisplatin directly into the cervical tumor, while lowering drug accumulation and consequent side effects in normal tissues. Moving forward, these data will be used as the basis of a future first-in-human clinical trial to test the efficacy of localized cisplatin as adjuvant or neoadjuvant chemotherapy in local and regional cervical cancer.
Authors: M Morris; P J Eifel; J Lu; P W Grigsby; C Levenback; R E Stevens; M Rotman; D M Gershenson; D G Mutch Journal: N Engl J Med Date: 1999-04-15 Impact factor: 91.245
Authors: Barbara Muz; Maurizio Buggio; Feda Azab; Pilar de la Puente; Mark Fiala; Mahesh V Padval; David T Weaver; Jonathan A Pachter; Ravi Vij; Abdel Kareem Azab Journal: Haematologica Date: 2019-01-17 Impact factor: 9.941
Authors: Marc Arbyn; Elisabete Weiderpass; Laia Bruni; Silvia de Sanjosé; Mona Saraiya; Jacques Ferlay; Freddie Bray Journal: Lancet Glob Health Date: 2019-12-04 Impact factor: 26.763
Authors: Li Gao; Shang Cai; Awei Cai; Yang Zhao; Tangbing Xu; Yan Ma; Yan Xu; Yuan Wang; Hao Wang; Yong Hu Journal: Drug Deliv Date: 2019-12 Impact factor: 6.419
Authors: Carlos Contreras-Romero; Eloy-Andrés Pérez-Yépez; Antonio Daniel Martinez-Gutierrez; Alma Campos-Parra; Alejandro Zentella-Dehesa; Nadia Jacobo-Herrera; César López-Camarillo; Guillermo Corredor-Alonso; Jaime Martínez-Coronel; Mauricio Rodríguez-Dorantes; David Cantu de León; Carlos Pérez-Plasencia Journal: Front Oncol Date: 2022-03-03 Impact factor: 6.244
Authors: Kinan Alhallak; Amanda Jeske; Pilar de la Puente; Jennifer Sun; Mark Fiala; Feda Azab; Barbara Muz; Ilyas Sahin; Ravi Vij; John F DiPersio; Abdel Kareem Azab Journal: Sci Rep Date: 2021-09-29 Impact factor: 4.379